Compare Alcon AG (ALC) vs BridgeBio Pharma Inc (BBIO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alcon AG vs BridgeBio Pharma Inc — how do they compare? Alcon AG trades at $74.19 (market cap $35.19B), while BridgeBio Pharma Inc trades at $83.9 (market cap $16.61B). The key difference: Alcon AG is far larger — about 2.1× BridgeBio Pharma Inc's market cap, and Alcon AG pays a 0.49% dividend while BridgeBio Pharma Inc pays none. Which is the better fit depends on your goals.
| ALC | BBIO | |
|---|---|---|
Market Cap | $35.19B | $16.61B |
Sector | Health | Health |
52-Week High | $90.12 | $90.17 |
52-Week Low | $62.02 | $47.29 |
Enterprise Value | $39.03B | $18.16B |
Dividend Yield | 0.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALC trades at $71.81, up 3.26% today, with a bullish technical signal supported by moving averages and ADX indicators. The company reported Q2 2026 EPS of $0.84, beating estimates, and raised its profit guidance on August 11, 2026, citing strong product launches. Revenue grew to $10.4B in 2025, though net income margin dipped to 9.42%. Valuation ratios include a P/E of 43 and P/S of 3.34, reflecting premium pricing.
Outlook is positive with analyst consensus at 54% buy ratings and a 27.8% upside target, but risks include margin pressure and high debt. The stock offers growth potential from innovation but faces competitive and macroeconomic headwinds.
BridgeBio Pharma (BBIO) trades at $84.48, up 2.03% with bullish technical signals from moving averages. Despite strong revenue growth from $222M in 2024 to $502M in 2025, the company reports significant losses with a -144.39% net margin. Recent FDA acceptance for encaleret in ADH1 and Attruby's commercial expansion in ATTR-CM provide growth catalysts, though cash flow remains negative at -$111M in 2025.
The stock presents high-risk growth potential with 88% analyst buy ratings and $102.20 consensus target, but faces substantial execution risks from ongoing losses and $1.72B debt load. Success hinges on pipeline approvals and Attruby's market penetration, making it suitable for risk-tolerant investors betting on biotech breakthroughs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alcon AG
Alcon, headquartered in Fort Worth, Texas, is the global eyecare leader with a diverse portfolio in ophthalmology including contact lenses, eye drops, surgical equipment, and related surgical products. Novartis purchased Alcon from Nestle in 2010 and, following nine years as a Novartis subsidiary, the company was spun off as a public company in April 2019. The company reports five distinct segments: implantables (16% of revenue), consumables (31%), equipment (9%), contact lenses (27%), and ocular health (17%). The company is geographically diversified, with only about 40% of revenue from the U.S. market, and the firm has a strong presence in the European Union and Japan.
Read more on ALC →About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →
